Impact BioMedical Inc. (IBO) shareholders
Close on Oct 19, 2026Market cap $329.93MP/E –Yield –
Ownership
Who owns Impact BioMedical's shares
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Frank D. Heuszel | Chief Executive Officer, Director | 97,344 | 0.09% | Dec 9, 2024 |
| Mark Suseck | Chief Operating Officer | 32,112 | 0.03% | Nov 5, 2026 |
| Todd D. Macko | Chief Financial Officer | 16,462 | 0.02% | Nov 5, 2026 |
| Castel Berisford Hibbert | Director | 32,112 | 0.03% | Nov 5, 2026 |
| Heng Fai Ambrose Chan | Director, 10% owner | 32,112 | 0.03% | Nov 5, 2026 |
| Jason Grady | Director | 28,164 | 0.03% | Nov 5, 2026 |
| Melissa Kaye Sims | Director | 32,112 | 0.03% | Nov 5, 2026 |
| David K. Keene | Director | 32,112 | 0.03% | Nov 5, 2026 |
| Christian Thomas Zimmerman | Director | 32,112 | 0.03% | Nov 5, 2026 |
| Elise Brownell | Director | 32,112 | 0.03% | Nov 5, 2026 |
| Dss, Inc. | 10% owner | 589,518 | 0.55% | Sep 24, 2026 |
| International Ltd Alset | 10% owner | 734,058 | 0.68% | Apr 4, 2025 |
| Inc. Alset | 10% owner | 0 | – | Apr 4, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Mark Suseck Chief Operating Officer | Oct 7, 2026 | Award | −4,170 | $4.54 | $18.93K | 32,112 |
| Christian Thomas Zimmerman Director | Oct 7, 2026 | Award | −4,170 | $4.54 | $18.93K | 32,112 |
| Castel Berisford Hibbert Director | Oct 7, 2026 | Award | −4,170 | $4.54 | $18.93K | 32,112 |
| Melissa Kaye Sims Director | Oct 7, 2026 | Award | −4,170 | $4.54 | $18.93K | 32,112 |
| David K. Keene Director | Oct 7, 2026 | Award | −4,170 | $4.54 | $18.93K | 32,112 |
| Elise Brownell Director | Oct 7, 2026 | Award | −4,170 | $4.54 | $18.93K | 32,112 |
| Heng Fai Ambrose Chan Director, 10% owner | Oct 7, 2026 | Award | −4,170 | $4.54 | $18.93K | 32,112 |
| Jason Grady Director | Oct 7, 2026 | Award | −4,170 | $4.54 | $18.93K | 28,164 |
| Todd D. Macko Chief Financial Officer | Oct 7, 2026 | Award | −4,170 | $4.54 | $18.93K | 16,462 |
| Dss, Inc. 10% owner | Sep 24, 2026 | Sale | −156 | $7.06 | $1.10K | 589,518 |
| Dss, Inc. 10% owner | Sep 23, 2026 | Sale | −27 | $6.95 | $188 | 589,674 |
| Dss, Inc. 10% owner | Sep 22, 2026 | Sale | −723 | $0.55 | $398 | 589,701 |
| Todd D. Macko Chief Financial Officer | Mar 27, 2026 | Sale | −43,400 | $0.56 | $24.30K | 155,122 |
| Todd D. Macko Chief Financial Officer | Mar 25, 2026 | Sale | −1,600 | $0.60 | $960 | 198,122 |
| Jason Grady Director | Mar 23, 2026 | Sale | −50,000 | $0.65 | $32.50K | 250,182 |
| Dss, Inc. 10% owner | May 27, 2025 | Sale | −45,400 | $0.54 | $24.52K | 545,024 |
| Dss, Inc. 10% owner | May 27, 2025 | Sale | −45,400 | $0.54 | $24.52K | 0 |
| Dss, Inc. 10% owner | May 22, 2025 | Sale | −115,600 | $0.55 | $63.58K | 590,424 |
| Dss, Inc. 10% owner | May 22, 2025 | Sale | −115,600 | $0.55 | $63.58K | 45,400 |
| Dss, Inc. 10% owner | Apr 4, 2025 | Sale | −890,800 | $0.95 | $846.26K | 161,100 |
| Inc. Alset 10% owner | Apr 4, 2025 | Sale | −180,000 | $0.96 | $172.80K | 0 |
| Heng Fai Ambrose Chan Director | Apr 3, 2025 | Sale | −351,555 | $0.50 | $175.78K | 0 |
| Inc. Alset 10% owner | Apr 3, 2025 | Sale | −273,286 | $0.78 | $213.16K | 180,000 |
| Inc. Alset 10% owner | Apr 3, 2025 | Sale | −351,631 | $0.58 | $203.95K | 0 |
| Inc. Alset 10% owner | Apr 2, 2025 | Sale | −382,427 | $0.58 | $221.81K | 351,631 |
| Inc. Alset 10% owner | Apr 2, 2025 | Sale | −2,349 | $0.67 | $1.57K | 351,555 |
| Inc. Alset 10% owner | Apr 2, 2025 | Sale | −200,000 | $0.67 | $134.00K | 353,904 |
| Inc. Alset 10% owner | Apr 2, 2025 | Sale | −300,000 | $0.58 | $174.00K | 553,904 |
| International Ltd Alset 10% owner | Apr 1, 2025 | Sale | −1,176,918 | $1.08 | $1.27M | 734,058 |
| International Ltd Alset 10% owner | Apr 1, 2025 | Sale | −650,000 | $1.45 | $942.50K | 1,910,976 |
| International Ltd Alset 10% owner | Apr 1, 2025 | Sale | −400,000 | $0.98 | $392.00K | 853,904 |
| International Ltd Alset 10% owner | Mar 31, 2025 | Sale | −300,000 | $1.03 | $309.00K | 1,253,904 |
| Dss, Inc. 10% owner | Mar 27, 2025 | Sale | −47,681 | $2.50 | $119.20K | 1,051,800 |
| Dss, Inc. 10% owner | Mar 26, 2025 | Sale | −9,858 | $3.15 | $31.05K | 1,099,481 |
| Dss, Inc. 10% owner | Mar 26, 2025 | Sale | −48,281 | $3.13 | $151.12K | 1,109,339 |
| Dss, Inc. 10% owner | Mar 21, 2025 | Sale | −166,600 | $3.30 | $549.78K | 1,178,882 |
| Dss, Inc. 10% owner | Mar 21, 2025 | Sale | −166,600 | $3.30 | $549.78K | 0 |
| Dss, Inc. 10% owner | Mar 21, 2025 | Sale | −166,600 | $3.30 | $549.78K | 0 |
| Dss, Inc. 10% owner | Mar 20, 2025 | Buy | +200 | $1.55 | $310 | 53,280 |
| Dss, Inc. 10% owner | Mar 20, 2025 | Sale | −53,280 | $4.68 | $249.35K | 0 |
| Frank D. Heuszel Chief Executive Officer, Director | Dec 5, 2024 | Buy | +500 | $2.26 | $1.13K | 97,344 |
| Dss, Inc. 10% owner | Dec 2, 2024 | Sale | −20 | $2.90 | $58 | 53,080 |
| Frank D. Heuszel Chief Executive Officer, Director | Nov 27, 2024 | Buy | +500 | $2.61 | $1.31K | 96,844 |
| Frank D. Heuszel Chief Executive Officer, Director | Nov 26, 2024 | Buy | +550 | $2.63 | $1.45K | 95,844 |
| Frank D. Heuszel Chief Executive Officer, Director | Nov 26, 2024 | Buy | +500 | $2.59 | $1.30K | 96,344 |
| Dss, Inc. 10% owner | Nov 18, 2024 | Sale | −5,000 | $3.02 | $15.10K | 53,100 |
| Dss, Inc. 10% owner | Nov 13, 2024 | Sale | −200 | $2.80 | $560 | 58,100 |
| Dss, Inc. 10% owner | Nov 12, 2024 | Sale | −500 | $2.76 | $1.38K | 58,300 |
| Dss, Inc. 10% owner | Sep 18, 2024 | Buy | +1,000 | $2.33 | $2.33K | 58,800 |
| Dss, Inc. 10% owner | Sep 17, 2024 | Buy | +7,800 | $2.40 | $18.72K | 57,800 |
| Dss, Inc. 10% owner | Sep 16, 2024 | Buy | +50,000 | $2.69 | $134.50K | 50,000 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.
Short interest
Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)
Shares sold short, last 12 months
Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Impact BioMedical's stock actually held short. Settlement fails (shares not delivered on time) peaked at 8,465 shares on Sep 18, 2026 over the last 90 days.
See a number that looks wrong?